Managers / Q1 2021 · view latest →
Sivik Global Healthcare LLC
CIK 0001596452 · 133 TACONIC RD, GREENWICH, CT, 06831 · 203-769-8600
Reported Value
$274M
Q1 2021
Positions
47
Filings on Record
30
2019–present window
Filed
May 12, 2021
original filing
Summary
Sivik Global Healthcare LLC reported $274M in U.S.-listed holdings across 47 positions for Q1 2021.
Its largest position, ZBH, represents 3.8% of the portfolio.
Compared with Q4 2020, the fund opened 20 new positions and exited 11.
Portfolio Metrics
Turnover
+27.5%
vs prior filed quarter
Top-10 Concentration
+33.3%
share of reported value
Largest Position
+3.8%
Zimmer Biomet
New / Exited
20 / 11
positions this quarter
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 92.3% · $253M
- Other · 4.3% · $12M
- ADR · 3.4% · $9M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| AAgilent Technologies Inc | NEW | +75.0K | 75.0K | +$10M | $10M |
| ISRGIntuitive Surgical Inc | NEW | +10.0K | 10.0K | +$7M | $7M |
| CORAmerisourceBergen Corp | NEW | +57.5K | 57.5K | +$7M | $7M |
| WATWaters Corp | NEW | +21.5K | 21.5K | +$6M | $6M |
| FMSFresenius Medical Care AG & C | NEW | +145.0K | 145.0K | +$5M | $5M |
| BRKRBruker Corp | NEW | +80.0K | 80.0K | +$5M | $5M |
| PPD Inc | NEW | +110.0K | 110.0K | +$4M | $4M |
| GMEDGlobus Medical Inc | NEW | +65.0K | 65.0K | +$4M | $4M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2021
47 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ZBHZimmer Biomet Holdings Inchistory → | Cash Securities | 3.79% | $10M | 65.0K |
| 2 | THCTenet Healthcare Corphistory → | Cash Securities | 3.79% | $10M | 200.0K |
| 3 | AAgilent Technologies Inchistory → | Cash Securities | 3.48% | $10M | 75.0K |
| 4 | MDTMedtronic PLChistory → | Cash Securities | 3.45% | $9M | 80.0K |
| 5 | BSXBoston Scientific Corphistory → | Cash Securities | 3.17% | $9M | 225.0K |
| 6 | IQVIQVIA Holdings Inchistory → | Cash Securities | 3.17% | $9M | 45.0K |
| 7 | UHSUniversal Health Services Inchistory → | Cash Securities | 3.16% | $9M | 65.0K |
| 8 | SYKStryker Corphistory → | Cash Securities | 3.11% | $9M | 35.0K |
| 9 | DHRDanaher Corphistory → | Cash Securities | 3.08% | $8M | 37.5K |
| 10 | HUMHumana Inchistory → | Cash Securities | 3.06% | $8M | 20.0K |
| 11 | MOHMolina Healthcare Inchistory → | Cash Securities | 2.98% | $8M | 35.0K |
| 12 | CNCCentene Corphistory → | Cash Securities | 2.91% | $8M | 125.0K |
| 13 | TMOThermo Fisher Scientific Inchistory → | Cash Securities | 2.91% | $8M | 17.5K |
| 14 | ABTAbbott Laboratorieshistory → | Cash Securities | 2.84% | $8M | 65.0K |
| 15 | Catalent Inc | Cash Securities | 2.78% | $8M | 72.5K |
| 16 | HCAHCA Healthcare Inchistory → | Cash Securities | 2.75% | $8M | 40.0K |
| 17 | UNHUnitedHealth Group Inchistory → | Cash Securities | 2.71% | $7M | 20.0K |
| 18 | ISRGIntuitive Surgical Inchistory → | Cash Securities | 2.69% | $7M | 10.0K |
| 19 | EHCEncompass Health Corphistory → | Cash Securities | 2.69% | $7M | 90.0K |
| 20 | BDXBecton Dickinson and Cohistory → | Cash Securities | 2.66% | $7M | 30.0K |
| 21 | CORAmerisourceBergen Corphistory → | Cash Securities | 2.48% | $7M | 57.5K |
| 22 | BAXBaxter International Inchistory → | Cash Securities | 2.46% | $7M | 80.0K |
| 23 | Charles River Laboratories In | Cash Securities | 2.38% | $7M | 22.5K |
| 24 | Laboratory Corp of America Ho | Cash Securities | 2.33% | $6M | 25.0K |
| 25 | WATWaters Corphistory → | Cash Securities | 2.23% | $6M | 21.5K |
| 26 | MCKMcKesson Corphistory → | Cash Securities | 2.13% | $6M | 30.0K |
| 27 | AVTRAvantor Inchistory → | Cash Securities | 2.11% | $6M | 200.0K |
| 28 | JNJJohnson & Johnsonhistory → | Cash Securities | 2.10% | $6M | 35.0K |
| 29 | FMSFresenius Medical Care AG & Chistory → | Cash Securities | 1.95% | $5M | 145.0K |
| 30 | BRKRBruker Corphistory → | Cash Securities | 1.88% | $5M | 80.0K |
| 31 | BMRNBioMarin Pharmaceutical Inchistory → | Cash Securities | 1.65% | $5M | 60.0K |
| 32 | PPD Inc | Cash Securities | 1.52% | $4M | 110.0K |
| 33 | GMEDGlobus Medical Inchistory → | Cash Securities | 1.46% | $4M | 65.0K |
| 34 | HRCHill-Rom Holdings Inchistory → | Cash Securities | 1.41% | $4M | 35.0K |
| 35 | BIOBio-Rad Laboratories Inchistory → | Cash Securities | 1.35% | $4M | 6.5K |
| 36 | BIIBBiogen Inchistory → | Cash Securities | 1.28% | $3M | 12.5K |
| 37 | VRTXVertex Pharmaceuticals Inchistory → | Cash Securities | 1.18% | $3M | 15.0K |
| 38 | HAEHaemonetics Corphistory → | Cash Securities | 1.01% | $3M | 25.0K |
| 39 | INNVInnovage Holding Corp | Cash Securities | 0.80% | $2M | 85.0K |
| 40 | BNTXBioNTech SE | Cash Securities | 0.80% | $2M | 20.0K |
| 41 | QUREuniQure NV | Cash Securities | 0.76% | $2M | 61.8K |
| 42 | MRNAModerna Inc | Cash Securities | 0.72% | $2M | 15.0K |
| 43 | ARGXArgenx SE | Cash Securities | 0.65% | $2M | 6.5K |
| 44 | Mirati Therapeutics Inc | Cash Securities | 0.62% | $2M | 10.0K |
| 45 | GHGuardant Health Inc | Cash Securities | 0.56% | $2M | 10.0K |
| 46 | SRPTSarepta Therapeutics Inc | Cash Securities | 0.54% | $1M | 20.0K |
| 47 | Turning Point Therapeutics In | Cash Securities | 0.45% | $1M | 13.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $132M | 34 | Apr 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $345M | 49 | Jan 21, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $344M | 44 | Oct 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $368M | 46 | Jul 25, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $185M | 31 | Apr 22, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $190M | 38 | Jan 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $236M | 35 | Nov 6, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $278M | 38 | Jul 29, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $427M | 47 | May 1, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $239M | 39 | Feb 5, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $198M | 33 | Nov 7, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $428M | 43 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $233M | 40 | May 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $213M | 39 | Feb 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $180M | 41 | Nov 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $176M | 38 | Aug 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $242M | 49 | May 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $233M | 45 | Feb 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $419M | 43 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $512M | 49 | Aug 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $274M | 47 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $245M | 38 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $232M | 38 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $302M | 52 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $253M | 40 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $269M | 50 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $198M | 45 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $414M | 62 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $271M | 61 | May 8, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $186M | 48 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.